首页> 外文期刊>Hepato-gastroenterology. >The relation between pathological complete response and clinical outcome in patients with rectal cancer
【24h】

The relation between pathological complete response and clinical outcome in patients with rectal cancer

机译:直肠癌患者病理完全缓解与临床预后的关系

获取原文
获取原文并翻译 | 示例
       

摘要

Background/Aims: Preoperative chemoradiotherapy (CRT) is the standard treatment modality in locally advanced rectal cancer. The primary aim was to correlate pathological complete response (pCR) with patient outcome, and the secondary objective was to identify predictive factors of pCR. Methodology: Patients with clinical stage II/III rectal cancer who received preoperative CRT between 2002 and 2010 were retrospectively studied. The median radiotherapy dose was 54 Gy (range, 45 to 64 Gy), and all patients received concurrent infusional 5-fluorouracil-based chemotherapy. Results: Median follow-up time was 48.3 months (range, 24 to 96 months) and 51 months (range, 44 to 110 months) for no-pCR and pCR groups, respectively. Eighteen patients (18.6%) had pCR. The 5-year overall survival was 95% for patients with pCR and 74.8% in patients without pCR (p=0.009). The 5-year local relapse free survival was 87.5% and 95% for the no-pCR and pCR groups, respectively (p=0.09). The 5-year distant relapse free survival was 93% in pCR group and 79.8% in no-pCR group (p=0.02). The 5-year distant free survival was 94% and 66% in patients with and without pCR, respectively (p=0.017). The clinical T4 (p=0.043) and pretreatment carcinoembryonic antigen level (CEA) >5ng/mL (p=0.012) were significantly associated with a lower pCR rate. In the multivariate logistic regression analysis, pretreatment CEA level >5ng/mL (p=0.008) was the only independent factor associated with a lower pCR rate. Conclusions: Patients with pCR after preoperative CRT had a significantly improved outcome. Furthermore, the pretreatment CEA level was independently associated with pCR.
机译:背景/目的:术前放化疗是局部晚期直肠癌的标准治疗方法。主要目的是将病理完全缓解(pCR)与患者预后相关联,而次要目的是确定pCR的预测因素。方法:回顾性研究2002年至2010年间接受术前CRT治疗的临床II / III期直肠癌患者。中位放疗剂量为54 Gy(范围为45至64 Gy),所有患者均接受了同时输注基于5氟尿嘧啶的化疗。结果:无pCR组和pCR组的中位随访时间分别为48.3个月(24至96个月)和51个月(44至110个月)。 18例(18.6%)患有pCR。有pCR的患者的5年总生存率为95%,无pCR的患者为74.8%(p = 0.009)。 no-pCR和pCR组的5年局部无复发生存率分别为87.5%和95%(p = 0.09)。 pCR组的5年远距离无复发生存率为93%,no-pCR组为79.8%(p = 0.02)。有和没有pCR的患者的5年远距离游离生存率分别为94%和66%(p = 0.017)。临床T4(p = 0.043)和治疗前癌胚抗原水平(CEA)> 5ng / mL(p = 0.012)与较低的pCR率显着相关。在多元逻辑回归分析中,治疗前CEA水平> 5ng / mL(p = 0.008)是与较低pCR率相关的唯一独立因素。结论:术前CRT后的pCR患者的预后明显改善。此外,预处理CEA水平与pCR独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号